Full-Time

Medical Advisor

Confirmed live in the last 24 hours

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior, Expert

Noida, Uttar Pradesh, India

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Scientific and or a master’s degree in a scientific discipline
  • Excellent oral and written communication and interpersonal skills
  • Ability to communicate internally and externally using the different channel mix
  • Excellent project management skills
  • Excellent presentation skills
  • High level analytical and conceptual thinking
Responsibilities
  • Execution of the Medical Affairs Plan(s) for pre-launch and/or newly launched products/indications
  • Developing and enhancing professional relationships and partnerships with healthcare professionals and other healthcare ecosystem stakeholders
  • Providing scientific, technical, and pharmaco-economic information to HCPs and key stakeholders
  • Engaging in peer-to-peer level dialogue with key customers
  • Responding to unsolicited customer inquiries and providing focused and balanced clinical/scientific information
  • Identifying and establishing relationships with key customers and other scientific thought leaders
  • Organizing and facilitating scientific events such as MSL events, Symposiums, Scientific Exchanges, Advisory Boards/Expert Panels
  • Identifying gaps in the patient experience journey as insights to be included in the medical/product strategies
  • Developing peer-level relationships with medical and scientific experts
  • Supporting data generation activities including participating in reviews of Investigator sponsored studies
  • Leveraging digital and innovation/technology as enablers for scientific exchange
Desired Qualifications
  • Doctoral degree in a scientific discipline (e.g. M.D., Ph.D., Pharm.D.)
  • Experience in pharmaceutical industry, regulatory environment, clinical or preclinical research, and knowledge of a therapeutic area disease state and treatment
  • Experience with basic research, drug discovery, drug development and KEE interactions

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca distinguishes itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-powered tools enhance AstraZeneca's lung cancer detection capabilities, improving early diagnosis.
  • Enhertu shows significant improvement in breast cancer treatment, boosting AstraZeneca's oncology portfolio.
  • Calquence's EU approval for CLL offers a competitive edge in leukemia treatment.

What critics are saying

  • Discontinuation of CAPItello-280 trial impacts AstraZeneca's oncology pipeline and investor confidence.
  • Operational challenges at the new CAR-T facility may delay cell therapy production.
  • AI reliance in lung cancer detection poses risks related to data privacy and accuracy.

What makes AstraZeneca unique

  • AstraZeneca's Open Innovation program accelerates drug discovery through shared compounds and technologies.
  • The A.Catalyst Network fosters global collaboration and innovation in health through 20+ hubs.
  • AstraZeneca's focus on Oncology, Cardiovascular, and Respiratory areas sets it apart in biopharma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

MocoShow
May 9th, 2025
AstraZeneca Opens $300 Million CAR-T Manufacturing Facility in Rockville, Creating Over 150 Jobs

AstraZeneca opens $300 million CAR-T manufacturing facility in Rockville, creating over 150 jobs.

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

PharmiWeb
May 7th, 2025
Enhertu Followed By Thp Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In Patients With High-Risk Her2-Positive Early-Stage Breast Cancer In Destiny-Breast11 Phase Iii Trial

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer. Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favouring Enhertu followed by THP compared to standard of care. The trial will continue to follow EFS

Cision
May 7th, 2025
Enhertu Improved Pcr In Early-Stage Breast Cancer

Enhertu improved pCR in early-stage breast cancer

Bethesda Magazine
May 6th, 2025
AstraZeneca opens cell therapy manufacturing site in Rockville

AstraZeneca announced in February 2024 that it was investing in the Rockville manufacturing facility.